Gene · 54890
Papers4,144
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
821 to 840 of 4,144
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The m6A-related gene signature stratifies poor prognosis patients and characterizes immunosuppressive microenvironment in hepatocellular carcinoma. | Front Immunol | 2023 | 37691948 | PubTator, text mining | PubMed |
| The Regulation of Ferroptosis by Noncoding RNAs. | Int J Mol Sci | 2023 | 37686142 | PubTator, text mining | PubMed |
| SMAD Proteins in TGF-β Signalling Pathway in Cancer: Regulatory Mechanisms and Clinical Applications. | Diagnostics (Basel) | 2023 | 37685308 | PubTator, text mining | PubMed |
| The synergistic effect of EMT regulators and m6A modification on prognosis-related immunological signatures for ovarian cancer. | Sci Rep | 2023 | 37684273 | PubTator, text mining | PubMed |
| eIF3d controls the persistent integrated stress response. | Mol Cell | 2023 | 37683648 | PubTator, text mining | PubMed |
| Effects of Gestational Arsenic Exposures on Placental and Fetal Development in Mice: The Role of Cyr61 m6A. | Environ Health Perspect | 2023 | 37682722 | PubTator, text mining | PubMed |
| Changes in m6A RNA methylation of goat lung following PPRV infection. | Heliyon | 2023 | 37681172 | PubTator, text mining | PubMed |
| Emerging role of METTL3 in inflammatory diseases: mechanisms and therapeutic applications. | Front Immunol | 2023 | 37671161 | PubTator, text mining | PubMed |
| N6-methyladenosine modification of PLOD2 causes spermatocyte damage in rats with varicocele. | Cell Mol Biol Lett | 2023 | 37670228 | PubTator, text mining | PubMed |
| N6 -methyladenosine-modified circFUT8 competitively interacts with YTHDF2 and miR-186-5p to stabilize FUT8 mRNA to promote malignant progression in lung adenocarcinoma. | Thorac Cancer | 2023 | 37669906 | PubTator, text mining | PubMed |
| The roles and therapeutic implications of messenger RNA internal N7 -methylguanosine and N6 -methyladenosine modifications in chemoresistance. | Clin Transl Med | 2023 | 37667528 | PubTator, text mining | PubMed |
| Immunological characterization and diagnostic models of RNA N6-methyladenosine regulators in Alzheimer's disease. | Sci Rep | 2023 | 37666846 | PubTator, text mining | PubMed |
| Pyrimidine metabolism regulator-mediated molecular subtypes display tumor microenvironmental hallmarks and assist precision treatment in bladder cancer. | Front Oncol | 2023 | 37664033 | PubTator, text mining | PubMed |
| RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA. | PeerJ | 2023 | 37663284 | PubTator, text mining | PubMed |
| Mechanisms of tumor-associated macrophages affecting the progression of hepatocellular carcinoma. | Front Pharmacol | 2023 | 37663266 | PubTator, text mining | PubMed |
| ALKBH5 in Colorectal Cancer: An Insufficiently Explored and Controversial Research Area. | Gastroenterology | 2023 | 37659670 | PubTator, text mining | PubMed |
METTL3-stabilized super enhancers-lncRNA SUCLG2-AS1 mediates the formation of a long-range chromatin loop between enhancers and promoters of SOX2 in metastasis and radiosensitivity of nasopharyngeal carcinoma. | Clin Transl Med | 2023 | 37658588 | PubTator, text mining | PubMed |
| Editorial: Unveiling the tumor microenvironment by machine learning to develop new immunotherapeutic strategies. | Front Immunol | 2023 | 37654480 | PubTator, text mining | PubMed |
| Recent advances in regulating the proliferation or maturation of human-induced pluripotent stem cell-derived cardiomyocytes. | Stem Cell Res Ther | 2023 | 37649113 | PubTator, text mining | PubMed |
| m6A-Mediated Biogenesis of circDDIT4 Inhibits Prostate Cancer Progression by Sequestrating ELAVL1/HuR. | Mol Cancer Res | 2023 | 37647111 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54890/papers?page=42